Scienture Holdings, Inc. (NASDAQ: SCNX) shares jumped 21.25% to $0.4046 in overnight trading following the announcement that commercial launch inventory for REZENOPY is complete. The company will begin shipments to U.S. pharmaceutical wholesalers in July, with retail availability expected in August. The stock move adds to a 0.48% surge recorded on Thursday, with volume reaching 7.82 million shares, significantly higher than the average daily volume of 398,400 shares.

REZENOPY is the highest-dose FDA-approved naloxone hydrochloride nasal spray available in the United States. It delivers 10 mg of naloxone hydrochloride in a single-use device for the emergency treatment of known or suspected opioid overdose. The product is designed to address overdoses involving highly potent synthetic opioids. The FDA approved the treatment on April 19, 2024.

According to IQVIA data for the 12 months ending April 2026, the U.S. naloxone market generated approximately $144 million in annual sales across 9.8 million units. Scienture has expanded payer access to reach more than 100 million covered lives to strengthen its commercial positioning. Scienture, LLC, a wholly-owned subsidiary of Scienture Holdings, secured exclusive U.S. commercialization rights for REZENOPY from Summit Biosciences Inc., a Kindeva subsidiary, in March 2025.

Commercial Strategy and Executive Commentary

Shankar Hariharan, Executive Chairman and co-CEO of Scienture, stated that the readiness for wholesale shipments marks a significant commercial milestone. He emphasized that the company is positioned to make REZENOPY broadly available to pharmacies, healthcare providers, and first responders in August.

Narasimhan Mani, President and co-CEO, noted that finalizing commercial launch inventory reflects the continued execution of the company's commercialization strategy. Following the launch of Arbli in October 2025, REZENOPY represents the continued expansion of Scienture's commercial portfolio.

Trading Metrics and Technical Analysis

Scienture Holdings has a market capitalization of $13.53 million, with a 52-week high of $2.60 and a 52-week low of $0.23. The stock is currently trading near its 52-week low. The Relative Strength Index (RSI) of SCNX stands at 34.79, while short interest is at 3.10%. Over the past 12 months, the stock has dropped 79.19%.

Scienture Holdings has expanded the commercial access and payor coverage for Arbli, adding approximately 12.5 million incremental covered lives nationwide. This growth includes expanded access through Medicare Part D supplement plans and other commercial and government-sponsored healthcare channels. The initiative aims to increase prescription volume and revenue growth for the proprietary oral suspension formulation of losartan potassium.

The company is strengthening Arbli's commercial infrastructure by targeting the expansion of pharmacy participation, relationships with pharmacy buying groups, specialty technology participation, and distribution capabilities. Scienture is also advancing initiatives to increase Medicaid access and expand Arbli's presence across additional healthcare channels.

Narasimhan Mani, President and co-CEO of Scienture, emphasized that expanding patient access remains a high priority. He stated that the addition of covered lives, coupled with a growing pharmacy network and channel partnerships, represents a step toward increasing awareness and utilization of Arbli.

Arbli is a proprietary oral suspension formulation of losartan potassium designed to improve patient access and compliance, particularly among pediatric, geriatric, and other patient populations with difficulty swallowing tablets. It operates within the approximately $219 million U.S. losartan market, which represents approximately 72 million prescriptions annually according to IQVIA MAT Apr 2026. By eliminating the variability and inconvenience associated with pharmacy compounding, Arbli delivers a consistent, convenient, and scalable solution for healthcare providers.

Shankar Hariharan, Executive Chairman and co-CEO of Scienture, highlighted the commercial opportunity, noting that even modest penetration among patients requiring a ready-to-use oral liquid formulation could represent a meaningful revenue opportunity. The company believes these initiatives build a strong foundation for long-term prescription growth.

Key Market Metrics